Davidson Capital Management Inc. Buys 4,579 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Davidson Capital Management Inc. raised its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 8.1% in the 1st quarter, HoldingsChannel.com reports. The firm owned 61,218 shares of the biopharmaceutical company’s stock after purchasing an additional 4,579 shares during the quarter. Halozyme Therapeutics comprises 1.1% of Davidson Capital Management Inc.’s portfolio, making the stock its 9th largest position. Davidson Capital Management Inc.’s holdings in Halozyme Therapeutics were worth $3,906,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the stock. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at $29,000. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics in the fourth quarter valued at $29,000. Smartleaf Asset Management LLC grew its position in Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics during the fourth quarter valued at about $69,000. Finally, UMB Bank n.a. increased its stake in Halozyme Therapeutics by 267.4% during the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 960 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 0.1%

HALO opened at $53.15 on Thursday. The firm has a market capitalization of $6.55 billion, a P/E ratio of 14.14, a P/E/G ratio of 0.35 and a beta of 1.19. The firm’s 50 day moving average is $56.97 and its 200-day moving average is $56.18. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $70.51. The company has a quick ratio of 7.30, a current ratio of 8.39 and a debt-to-equity ratio of 3.13.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.98 by $0.13. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. The business had revenue of $264.86 million during the quarter, compared to analyst estimates of $231.21 million. During the same period last year, the business earned $0.79 EPS. The business’s revenue was up 35.2% on a year-over-year basis. Analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on HALO shares. Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 7th. Leerink Partners cut shares of Halozyme Therapeutics from a “market perform” rating to an “underperform” rating and set a $47.00 price target on the stock. in a research report on Tuesday, May 13th. Benchmark downgraded shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Morgan Stanley downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $73.00 to $62.00 in a research note on Wednesday, May 14th. Finally, Leerink Partnrs lowered shares of Halozyme Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, May 13th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Hold” and an average price target of $61.90.

Insider Activity

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 503 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $64.05, for a total value of $32,217.15. Following the transaction, the director now directly owns 33,108 shares of the company’s stock, valued at $2,120,567.40. This represents a 1.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.